HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, Beauty And Wellness News: GNC, Vitamin Shoppe, NPA, AHPA

This article was originally published in The Rose Sheet

Executive Summary

Clock ticking on proxies for GNC's China proposal; 8 on Vitamin Shoppe Wellness Council; NPA lobby day has 200 meetings; and AHPA's Johnson presents at Canada's Natural Health Product Research conference.

You may also be interested in...



Health, Beauty And Wellness News: Medline Remedy Contamination, GNC Proxy

GNC Digital Sales Hot But Shareholders Slow To Warm To China Expansion Deal

GNC’s Amazon storefront has an impact as the store and the firm’s website combine for 27% online sales growth in the first quarter. The firm delays a vote on a planned deal that would makes Harbin Pharmaceutical its largest shareholder, with a board voting bloc of five seats, and would launch a JV by the firms to expand GNC's presence in China.

SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill

The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel